INFLARX N.V. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1.43 USD | 0.00% |
|
-0.69% | -12.27% |
| 08/05 | InflaRx N.V. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
| 21/03 | Transcript : InflaRx N.V. - Special Call |
Presentation Operator MessageOperator (Operator)Greetings. Welcome to the InflaRx conference c...
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe
Inflarx NV, formerly Fireman BV, is a holding company for InflaRx GmbH, a Germany-based clinical-stage biopharmaceutical company. The Company's primary focus is on the development of monoclonal antibodies targeting activation products of the complement system for application in the treatment of life-threatening inflammatory diseases. Its lead product candidate, IFX-1, is an intravenously delivered first-in-class anti-C5a monoclonal antibody, undergoing Phase II clinical trial for the treatment of Hidradenitis Suppurativa (HS), a rare and chronic debilitating systemic inflammatory skin disease, and entering Phase II clinical trial for the treatment of ANCA-associated vasculitis (AAV) and other rare autoimmune diseases. The Company's product pipeline also includes IFX-2, which is in preclinical development.
Calendar
05/06/2024
- R&D Day
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
1.319
EUR
Average target price
8.375
EUR
Spread / Average Target
+535.05%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -12.27% | 84.2M | |
| +11.91% | 114B | |
| +11.60% | 105B | |
| -4.68% | 23.83B | |
| -0.82% | 21.73B | |
| -10.12% | 18.1B | |
| -42.12% | 16.34B | |
| -17.47% | 16.13B | |
| +2.77% | 13.75B | |
| +34.58% | 11.76B |
- Stock Market
- Equities
- IFRX Stock
- News InflaRx N.V.
- Transcript : InflaRx N.V. - Special Call
